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The day school let out for the summer,
my daughter and I packed our bags for
Britain, where we had lived for a few
months in 2006. Annie was eager to
reconnect with her friends there, and I
had arranged to conduct three interviews.
In desperation and with the clock ticking, I
struggled to fit my bulky recorder into my
wheelie when it dawned on me that the
‘‘talk app’’ on my daughter’s iphone
should be up to the job. You can imagine
the reluctance and skepticism on the part
of my 15-year-old, but she managed to get
into the spirit and acquiesced.
First up on my schedule was Adrian
Bird (Image 1), who holds the Buchanan
Chair of Genetics at the University of
Edinburgh and is also Director of the
Wellcome Trust Centre for Cell Biology.
Long before the word ‘‘epigenome’’ was
coined, Bird began mapping the distribu-
tion of DNA methylation (occurring at the
cytosine of CpG dinucleotides) in the
genomes of a variety of species. His work
emerged just as agarose gels, restriction
enzymes, and Southern blots were being
developed. Bird later spawned the idea of
CpG islands, pockets of DNA rich in
unmethylated CpGs and frequently found
in conjunction with the promoter regions
of mammalian genes. Bird’s observation
provided a roadmap for disease gene
discovery for about 15 years, until human
genome draft sequences began to emerge.
Bird’s laboratory then went on to
identify proteins that bound to methylated
DNA, one of which (MeCP2) was discov-
ered years later to be defective in Rett
Syndrome, a rare X-linked disorder in
which affected girls develop autism and a
distinctive set of behaviors. This astonish-
ing turn of events propelled Bird to extend
his studies on MeCP2 to a murine model
for Rett Syndrome, ushering in new ideas
about therapy for this devastating illness,
but still leaving open the question of
MeCP2’s role in the brain.
Bird and his wife Cathy Abbott, also a
geneticist, invited me to spend the night
prior to the interview with them (future
interviewees, take note!), and I was delight-
ed to do so. Still jet-lagged, I traveled by
train, leaving behind the uncharacteristic
sun of Cambridge to find cold rain
penetrating the skylights at Edinburgh’s
Waverley Station. It felt very cozy to share
the evening with them and their children,
Tom and Annie: chatting, watching some
Twenty20 (an abbreviated form of cricket),
playing Uno, feeding the three guinea pigs,
and experimenting with the iphone’s tape
app, which, to our delight, worked.
Gitschier: My first question is a two-
part, integrated one. How did you get
interested in methylation, and what was
the state of the art at the time you started
working on it?
Bird: I first got interested when I was
in Zurich doing a post-doc.
Gitschier: Whom were youwiththere?
Bird: Max Birnstiel. I had been in the
States doing a post-doc [with Joe Gall at
Yale] on gene amplification in frog
oocytes. When I went to Max’s in Zurich,
he had a visitor named Ham Smith.
Gitschier: What year approximately
was this?
Bird: 1973–1974. Ham was on sabbat-
ical, and the first thing he did was to make
a restriction enzyme, HpaII—Haemophilus
parainfluenzae II.
I was making ribosomal RNA genes,
just for something to do really. We knew
there was a difference between the ampli-
fied ribosomal RNA genes, which were
extrachromosomal in the oocyte, and the
chromosomal ones, and that the difference
was due to methylation. Don Brown and
Igor Dawid had shown that chromosomal
rDNA had 5-methylcytosine and the
amplified didn’t.
Image 1. Adrian Bird.
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[extrachromosomal] DNA, and it cut
beautifully. But when I tried with purified
chromosomal ribosomal DNA, it didn’t
cut. It was known that restriction enzymes
were blocked by methylation in the
organisms from which they are derived;
there is usually a restriction enzyme and a
modification enzyme that matches it and
that protects the genomic DNA of the host
from its own destructive enzymes. So it
seemed that some of the methylation [in
the chromosomal rDNA] might be mim-
icking the blockage that occurs in the
Haemophilus parainfluenzae endogenous
enzyme.
Gitschier: Did Ham Smith know that
HpaII didn’t cut methylated DNA before
you did the experiment?
Bird: Probably, but he just made
restriction enzymes in order to make
himself at home. Restriction enzyme
technology was new, and agarose gels
had just been brought in. And another guy
there was Ed Southern, who had just
invented Southern blotting, so there was a
bit of coincidence here.
Gitschier: Was Ed on sabbatical?
Bird: Yes, he was as well. I can’t
remember whether they were there at
exactly the same time. I think they
overlapped.
Gitschier: So, why is everybody com-
ing to Max Birnstiel’s lab?
Bird: Max Birnstiel and Don Brown
were hotly competing groups because both
of them worked on ribosomal RNA genes,
which you could purify by buoyant density
centrifugation. Before you could clone
DNA, the only way to get hold of pure
gene was A) because it was highly repeated
and B) because its buoyant density was
different from the bulk [of the DNA]. So if
you ran enough cesium chloride gradients
you could get it pure and then you could
study the structure of it. Frog ribosomal
genes and sea urchin histone genes were
where it was AT in those days.
Gitschier: What attracted Ham to
that lab?
Bird: Max and Ham knew each other
and were friends.
Gitschier: So for him, it was going to a
friendly and interesting place. And Ed?
Bird: He came over to work with Max,
I have to say, partly because he was going
out with someone who happened to work
in Max’s lab. In those days, people’s
motives were more random than they
might be made to look now.
Gitschier: Sounds lovely. So Ham’s
making this enzyme, and you are just
trying this enzyme, you don’t know what
the results are going to be.
Bird: I’m not sure what I’m doing, to
be honest! I knew I wanted to do
something interesting, but I was just
playing around more than anything else.
Ham was playing around with the en-
zymes he knew about and Ed was doing
the technological things that he really liked
doing. So accidentally this gave rise to the
idea that one could use restriction enzymes
to map methylation in DNA. There was a
conjunction of areas that were needed
before one could exploit this properly, and
that didn’t happen until I got back to
Edinburgh.
By 1975, I was back there in an MRC
unit and mapping the methylated and
nonmethylated sites in the ribosomal genes
in Xenopus laevis. And it took absolutely
ages to get that published.
Gitschier: At some point you moved
away from frog oocytes.
Bird: We looked at sea urchins—
invertebrates—and found there was both
a methylated and an unmethylated frac-
tion of the genome. The last things we
came to were vertebrate cells and they
didn’t seem to have anything like what you
see in the invertebrates. When you digest-
ed the DNA with these methylation-
sensitive enzymes, nothing happened be-
cause most of the DNA is methylated.
Then we had the idea that maybe we
could see a small fraction of unmethylated
DNA if we end-labeled it. That was the
work of David Cooper who did a Ph.D. in
my lab. I can remember him doing the
first end-labeling, because it made a
horrible blob. Something that could be
artifactual, but it wasn’t, and we spent
quite a lot of time showing that. I cloned
mouse fragments derived from that blob,
and that was our 1985 paper in Cell. And
then we restriction-mapped them and
showed that they came from clusters of
nonmethylated CpGs in the genome.
We were not totally alone in reaching
these conclusions. Tykocinski and Max
had looked at DNA sequence in MHC
class I genes and saw these clusters, and
earlier a guy called De Crombrugghe also
saw something like this. There was also
stuff on the inactive X chromosome—
Barbara Migeon had seen nonmethylated
sequences at the 59 ends of genes.
It was in the air, but not yet an accepted
generalization. Our data really suggested
that there was a category of genomic DNA
that was full of CpGs that weren’t methyl-
ated and that eventually were understood to
be near promoters. So we kind of brought it
all together.
Gitschier: So you published this
review article [in Nature], which is where
I became familiar with your work.
Bird: Yes, that was cited loads of times,
because it was the mapping phase of the
genome project where people wanted to
map themselves into reality.
Gitschier: Well, people used them to
find genes. They were like little flags that
said, ‘‘Hey over here, I’m a gene!’’
Bird: Exactly.
Gitschier: Did you coin the name
‘‘CpG islands’’?
Bird: No I didn’t. We called them
‘‘HTF islands’’ for ‘‘HpaII tiny frag-
ments’’, but reviewers said, ‘‘What the
hell is HTF?’’ It was Marianne Frommer,
who was doing a sabbatical in my lab at
the time the Cell paper was published, who
called them CpG islands—it made more
sense.
Gitschier: OK, let’s switch gears. At
some point, you started to work on
proteins that bound to methylated regions.
Bird: That arose by chance as well.
The CpG islands provide an approximate
way to map methylation throughout the
genome, but at the time there was no way
to do that properly. So we kind of ran into
a brick wall—what you really want to
know is where the methyl groups are
throughout the genome.
Gitschier: And you found out where
they weren’t.
Bird: So I decided to work on how the
CpG islands might originate. We asked,
‘‘Does something bind to the nonmethy-
lated sequence that might protect it from
methylation?’’ Just by steric inhibition. We
made an oligonucleotide, and at the time it
took Amersham about 4 months to do it. I
just made up a sequence full of CpGs that
were in restriction enzyme sites so we
could test their methylation status, and
then we oligomerized them and methylat-
ed the sites using commercial enzymes,
because you could buy HhaI and HpaII
methyltransferases.
Then we made extracts from mouse
liver nuclei. And what we found was
something that bound to the methylated
one but not the unmethylated one. So
after a period of time where we considered
whether this was interesting or not, we
decided to work on isolating what bound
to the methylated DNA.
Gitschier: What year are we now?
Bird: This is 1984–1985.
Gitschier: So, if you already knew
about this protein you called MeCP1, why
did you go on to look for more methylat-
ed-DNA binding proteins?
Bird: We were trying to purify MeCP1,
and we were mucking about changing the
assay, and in doing that we detected another
protein. We couldn’t purify MeCP1 for
love nor money, but it has been purified
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could purify a different protein, which we
called MeCP2. It was relatively easy.
Gitschier: What, then, did you do
with……MePC2 [sic]?
Bird: Yeah—terrible name. Entirely
my fault. Like HTF islands. I have a talent
for inventing awkward names.
First thing we did was dissect out the
methyl-CpG binding domain. These were
not high-profile publications, because no
one was interested in MeCP2 for a long
time. Then we wanted to know if it was a
methyl-binding domain in vivo, as op-
posed to in vitro. And that is STILL an
issue that people are not convinced about.
But I am.
We showed that it went to the satellite
foci in mouse nuclei. In mouse, the
pericentromeric heterochromatin is quite
CpG rich and heavily methylated. MeCP2
goes there and stains in ‘‘spots’’. It’s about
10% of the genome, but contains half of all
the methylation. It was a nice visual way of
showing binding. Then we used a DNA
methyltransferase mutant that has much
lower levels of methylation, and we no
longer had staining of the heterochroma-
tin. So that said that it was the methylation
that was causing it to bind. That was quite
an important paper because it showed that
this mindless, in vitro assay that we used
for purification actually had some biolog-
ical relevance.
Next we decided we wanted to know
what MeCP2 did, so we knocked it out.
And then Zoghbi and Francke showed
that it was mutated in Rett Syndrome.
Gitschier: I didn’t appreciate that.
You actually did make a knockout before
they found it as the basis for Rett?
Bird: Yes. The reason you didn’t
appreciate it was because we didn’t get
the right result. In something like 1993, we
knocked it out. Because it’s on the X
chromosome, you’ve got a null immedi-
ately in male ES cells. We made chimeras
and the chimeras all died. We concluded
that it was an embryonic lethal.
By the time the Rett Syndrome story
came out, we had already decided to do it
again and made a conditional knockout. I
now think that growing ES cells in the
absence of MeCP2 somehow compromises
their ability to form embryos properly.
Gitschier: So you didn’t get a result
that was really wrong, you just didn’t get a
result that was really useful in studying
Rett Syndrome.
Bird: Correct. We actually started on
this conditional MeCP2 knockout before
the Rett Syndrome story came out. We
knocked MeCP2 out in early embryonic
development. Those [male] mice were
born and normal until about 6 weeks
and died at about 12 weeks. And then we
did it again just knocking out in neurons
and glia with the same result. This said the
phenotype was entirely due to the brain.
Gitschier: OK, so you’re working
away on trying to understand the function
in mice, and suddenly Zoghbi and Francke
labs discover that the gene you’ve been
working on has real human consequence.
Bird: Yeah.
Gitschier: Were you a reviewer on
that paper?
Bird: Yes.
Gitschier: What did you think when
you saw the paper?
Bird: I thought, ‘‘What the hell is Rett
Syndrome?’’
Gitschier: I was going to ask you that!
Bird: In my collection I did have
papers about it, but I hadn’t been keeping
up with it at all, honestly.
Gitschier: What else did you think?
Bird: I thought, well we’re already
working on these mice, so now let’s see if
we can make a model for Rett Syndrome
as well.
Gitschier: But what about the physi-
ological or mechanistic implications? The
fact that defects in a methyl-CpG binding
protein cause a neurological disorder
seems wild to me.
Bird: We’re working on that quite a lot
at the moment.
I think the people who were looking in
the interval for the gene that was mutated
were quite disappointed to find that it
wasn’t one of the GABA receptors, which
is in that region, but rather that it was this
rinky-dink little housekeeping gene. No
one could get terribly inspired by finding
it. But to me, it was great.
It is quite exhilarating to realize you
have some preliminary insights into some-
thing whose function turns out to be very
important. I had previously been rather
disparaging about medically relevant re-
search, considering that I was working on
pure knowledge and that biological infor-
mation was intrinsically important. But as
soon as you collide with biomedical
relevance, it changes your perspective. It
breathes life into the project and it has
added new dimensions to my research. I’m
absolutely delighted it happened.
But even now, not everybody agrees
about what MeCP2 does.
Gitschier: Let’s turn to that now,
because to me that is very murky.
Bird: The initial experiments said [the
following]: A) It’s a methylated-DNA
binding protein. B) It’s very abundant in
brain. In fact, that’s where we purified it
from. C) It’s associated with a co-repressor
called Sin3a and is able to repress
transcription in model systems by co-
transfection in cultured cells. So the
prevailing view is that it’s a methyl-CpG
binding repressor.
But, if you look in the knockout you find
a lot of genes go up and a lot of genes go
down, whereas you’d expect, if it’s a
repressor, that genes would only go up.
So this has made everyone think twice.
But another argument, which people
don’t usually find persuasive I have to say,
is that some genes going up and some
genes going down makes sense if MeCP2 is
regulating very many genes. Because
you’ve probably got a closed system—for
everything that goes up there must be
something that goes down. A good exam-
ple of this—if you treat cells with the
histone deacetylase inhibitor TSA (trichos-
tatin A), this causes histone acetylation to
go through the roof, which is a marker of
activity, but expression-wise as many
genes go up as go down. Everything would
LIKE to go up, but you can’t employ
more polymerases, etc., than are there.
We’ve been through phases where we
have been prepared to throw out all the
old stuff and say neurons are doing
something different with MeCP2. But the
data have forced us to come back to the
original idea that MeCP2 coats the
genome and recruits enzymes that deace-
tylate and keep the acetylation low.
So what is its function? Mike Greenberg
[Harvard Children’s Hospital] showed
that MeCP2 is a phosphoprotein. It gets
phosphorylated when neurons are active.
We know that when neurons fire, you get
bursts of synaptic protein synthesis and
nuclear protein synthesis and this is
associated with plasticity. It is an attractive
idea that MeCP2 has something to do with
that. Neurons fire—phosphorylation of
MeCP2 changes its properties—let’s say
it comes off, leading to a burst of
transcriptional activity, which is somehow
involved in neuronal homeostasis. It’s an
intriguing possibility.
To be honest, the reason that there are
so many theories about what MeCP2 does
is that none of them has been nailed down
experimentally. There is a bit of a vacuum
there, and people fill vacuums with
speculations, as they should. All of the
things I’m saying are subject to different
views from different people, but I would
say MeCP2 is involved in maintenance.
Gitschier: When you say mainte-
nance—do you mean maintaining the
neuron itself, or maintaining the neural
activity?
Bird: Functional integrity. What seems
to degrade in Rett Syndrome is neuronal
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you’d like to say is that neurons are
degenerate, but you’re not allowed to say
that, because neurodegenerative disorders,
like Alzheimer or Parkinson, involve
neuronal death.
Gitschier: We think of autism as a
neurodevelopmental defect and Rett as
being in that category as well, because its
onset is during the development of a
human being.
Bird: The reason that people are so
wedded to the idea of Rett being neuro-
developmental is that of course there are
lots of things going on in neurodevelop-
ment at the time girls get the symptoms.
What impresses me is that female mice get
equivalent symptoms between 4 and 12
months and humans between 6 and 18
months—in REAL time, that is the same,
more or less. But developmentally, they
are at totally different stages.
People see only these two categories
[neurodegenerative and neurodevelop-
mental], but I would say it’s a neuromain-
tenance disorder. The best evidence for
that is reversibility [see below].
Neurons are long-lived complex cells
that expend a lot of effort deciding who
they are going to be connected to. As a
neuron you’d better remember all that
because lots of things are going to happen
to this organism over a period of years, or
decades in our case, and that neuron will
not get a chance to renew. So mainte-
nance becomes an extremely important
problem, and I think MeCP2 is one of the
proteins that have evolved to ensure that.
In my opinion the reversibility experi-
ments that we did are interesting for all
sorts of disorders in which neuronal death
has not been established, and that includes
autism and schizophrenia, for example.
The general assumption is that once
you’ve got one of these neurological
disorders, that’s it. When one sees Down’s
Syndrome, or mental retardation of any
kind, it is ingrained in us to believe that
nothing can ever be done to reverse that.
Gitschier: Tell me about the revers-
ibility experiments.
Bird: That’s probably one of the most
impressive things we’ve ever done. I’ll
show you a movie. Neurons don’t die in
Rett Syndrome or in the mouse model. So
this raised the possibility that one could
put the gene back and find out whether
the symptoms are reversed. Jacky Guy
took MeCP2 and inserted a stop cassette
in an intron—designed to prevent expres-
sion, but flanked by loxP sites. When you
mate that with a mouse with Cre
expressed under estrogen receptor control,
you can inject tamoxifen, release Cre,
delete the stop, and presto transcription
starts again. It was one of those projects
where everything worked even though we
thought it might never work.
Here’s the life cycle of a male MeCP2
stop-cassette mouse. It is born and then
gets symptoms at 6–8 weeks and dies at 9–
16 weeks. We inject MeCP2 here, when
the mouse has advanced symptoms and is
near death. It doesn’t really move, very
low to the ground, feet splayed apart,
tremor, arrhythmic breathing. Now, here
is the same mouse 4 weeks later.
Gitschier: Oh my goodness. It looks
exactly like the control.
Bird: We’ve done this with many mice
and it’s consistently reversible. Females
breed normally for about 6 months, but
after that they hit a brick wall, become
inert and obese, develop hind limb
clasping, tremors, and arrhythmic breath-
ing—all the things that mimic aspects of
Rett Syndrome, and it is stable, just as in
humans, and lasts for the rest of their lives.
That is the real model for Rett Syndrome.
These animals are way beyond neurode-
velopment. But even at this late stage, it is
reversible. It establishes the principle that
Rett Syndrome, as least in mice, is
reversible, and it encourages the belief
that it might be reversible in humans, too.
I must say the reversal is the most
surprising result we’ve ever had, partly
because it went completely against what
was expected and partly because I’m a
biochemist at heart and this was a
sophisticated genetic problem. It was nice
to follow the problem into the mouse and
do an experiment that has had an impact
beyond Rett Syndrome and that many
neuroscientists find interesting. I’m now
on the fringes of that world, and I’d like to
try and make more contributions there.
Gitschier: So you’re not about to stop
soon, I take it!
Bird: Everybody knows that you your-
self are probably not the best person to
judge that, but I don’t feel in the slightest
like stopping.
When people write and say that the
mouse reversal has transformed their view
of prospects for their daughter, you are
flattered by that, but it very quickly gives
way to frustration—that you’ve raised
people’s hopes but you cannot in any
way replicate the reversal in humans.
Although it seems like a short step to a
lay person, in fact, it is a gigantic leap into
the unknown.
PLoS Genetics | www.plosgenetics.org 4 October 2009 | Volume 5 | Issue 10 | e1000667